Hyperprolactinemia as a Side Effect of Long-Acting Injectable Risperidone Therapy or a Symptom of Klinefelter Syndrome - a Diagnostic and Therapeutic Dilemma.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Psychiatria Danubina

• Publication date

  2018-03-16

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.24869/psyd.2018.99PMID 29546865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents

  2015cited by this paper
• Antipsychotics and Hyperprolactinemia : Prevalence and Risk Factors

  2015cited by this paper
• Guidelines for Antipsychotic-Induced Hyperprolactinemia

  2015cited by this paper
• The Interface of Stress and the HPA Axis in Behavioural Phenotypes of Mental Illness.

  2014cited by this paper
• A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis.

  2013cited by this paper
• Antipsychotic-Induced Hyperprolactinaemia

  2012cited by this paper
• Further evidence of the clinical, hormonal, and genetic heterogeneity of Klinefelter syndrome: a study of 216 infertile Egyptian patients.

  2012cited by this paper
• Bone Remodeling, Bone Mass and Weight Gain in Patients with Stabilized Schizophrenia in Real-Life Conditions Treated with Long-Acting Injectable Risperidone

  2011cited by this paper
• Gynecomastia: physiopathology, evaluation and treatment

  2011cited by this paper
• Risperidone versus other atypical antipsychotics for schizophrenia.

  2011cited by this paper
• Hyperprolactinemia associated with psychotropics—a review

  2010cited by this paper
• Psychiatric Characteristics in a Self-Selected Sample of Boys With Klinefelter Syndrome

  2009cited by this paper
• Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study

  2009cited by this paper
• Gynecomastia: pathophysiology, evaluation, and management.

  2009cited by this paper
• Increased prolactin secretion and thyrotrophin response to thyrotrophin releasing hormone in Klinefelter's syndrome.

  2009cited by this paper
• Prolactin awareness: an essential consideration for physical health in schizophrenia.

  2008cited by this paper
• Pituitary volume in psychosis: the first review of the evidence

  2008cited by this paper
• A review of the association between antipsychotic use and hyperprolactinaemia

  2008cited by this paper
• Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics

  2007cited by this paper
• Psychiatric morbidity and X-chromosomal origin in a Klinefelter sample.

  2007cited by this paper
• Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.

  2005cited by this paper
• Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study.

  2003cited by this paper
• What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?

  2003cited by this paper
• American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 135B:15–23 (2005) Klinefelter’s Syndrome (XXY) as a Genetic Model for Psychotic Disorders

  year unknowncited by this paper

• Evaluation of selected semen parameters and biomarkers of male infertility – preliminary study

  2022cites this paper
• Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review

  2020cites this paper